11 completed, 4 terminated, 3 unknown, 2 active not recruiting. 22 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 11, Terminated 4, Unknown 3, Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Breast Neoplasm: new trials by email Literature Review of Breast Neoplasm trials Research Report on Breast Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer MBQ-167 - Breast Cancer, Breast Neoplasm | Phase 1 | Recruiting | MBQ Pharma | 48 | 2023-11-09 | 2026-08-31 |
| Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors Injections Subcutaneously Talazoparib, Oral capsules Talazoparib - Advanced or Recurrent Solid Tumors, Breast Neoplasm | Phase 1 | Withdrawn | Center Trials & Treatment | 2022-11-10 | 2023-03-29 | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer G1T48, Palbociclib - Carcinoma, Ductal, Breast, Breast Cancer Female | Phase 1 | Completed | G1 Therapeutics, Inc. | 107 | 2018-05-09 | 2026-09-21 |
| Combination Study of SV-BR-1-GM With Retifanlimab SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation - Breast Cancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 36 | 2018-03-16 | 2026-03-27 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers UB-921, Herceptin - Breast Neoplasm | Phase 1 | Completed | United BioPharma | 18 | 2018-03-05 | 2019-04-03 |
| SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b - Breastcancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 24 | 2017-05-05 | 2021-01-29 |
| Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) Cyclophosphamide, Indomethacin, Omeprazole - Breast Neoplasm, Breast Neoplasm, Male | Phase 1 | Completed | Providence Health & Services | 16 | 2017-02-09 | 2025-12-03 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer G1T38, Fulvestrant - Carcinoma, Ductal, Breast, Breast Cancer | Phase 1 / Phase 2 | Unknown | G1 Therapeutics, Inc. | 102 | 2017-01-01 | 2023-02-15 |
| [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer [18F]FLT, PET/CT, ribociclib - Breast Neoplasm, Metastatic Breast Cancer | Phase 1 | Active not recruiting | University of Pennsylvania | 20 | 2015-11-01 | 2026-10-07 |
| 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients 131I-Tenatumomab - Breast Neoplasm, Head and Neck Neoplasm | Phase 1 | Terminated | sigma-tau i.f.r. S.p.A. | 2 | 2015-11-01 | 2018-09-18 |
| Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) Eribulin Mesylate, Pembrolizumab - Breast Neoplasm | Phase 1 / Phase 2 | Completed | Eisai Inc. | 258 | 2015-08-28 | 2022-05-05 |
| [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer [18F]ISO-1 - Breast Cancer, Breast Neoplasm | Phase 1 | Active not recruiting | University of Pennsylvania | 30 | 2015-03-11 | 2026-01-09 |
| Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer Stereotactic body radiotherapy (SBRT) - Breast Neoplasm | Phase 1 | Unknown | Juravinski Cancer Center | 32 | 2014-02-01 | 2015-03-31 |
| Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment Drug-AZD8931, Drug-Placebo - Breast Neoplasm | Phase 1 | Terminated | AstraZeneca | 3 | 2012-06-01 | 2012-12-17 |
| Multipeptide Vaccine for Advanced Breast Cancer hTERT/Survivin Multi-Peptide Vaccine - Breast Neoplasm, Breast Cancer | Phase 1 | Completed | University of Pennsylvania | 11 | 2007-11-01 | 2016-09-29 |
| A Study of MLN8054 in Patients With Advanced Solid Tumors MLN8054 - Breast Neoplasm, Colon Neoplasm | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 63 | 2005-10-01 | 2008-04-01 |
| Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 TAK-165 - Breast Neoplasm, Pancreatic Neoplasm | Phase 1 | Completed | Takeda | 16 | 2002-06-01 | 2012-02-02 |
| Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer rh IL-12, rh IL-2 - Kidney Neoplasm, Lung Neoplasm | Phase 1 | Terminated | National Cancer Institute (NCI) | 39 | 2000-04-28 | 2019-12-17 |
| Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer Monoclonal Antibody 3A1, Monoclonal Antibody 95-5-49, Monoclonal Antibody 95-6-22 - Breast Neoplasm, Neoplasm Metastasis | Phase 1 | Completed | National Cancer Institute (NCI) | 107 | 1996-07-12 | 2018-12-21 |
Showing 20 of 22. Sign in to see all of them.
Breast Neoplasms (22) · Pancreatic Neoplasms (4) · Neoplasm Metastasis (3) · Neoplasms (3) · Carcinoma, Ductal (2) · Carcinoma, Ductal, Breast (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Kidney Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1)
Breast Diseases (22) · Neoplasms by Site (22) · Skin Diseases (22) · Skin and Connective Tissue Diseases (22) · Neoplasms (19) · Neoplasms by Histologic Type (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Carcinoma (4) · Digestive System Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Neoplasms, Ductal, Lobular, and Medullary (4)
Cyclophosphamide (3) · pembrolizumab (2) · Alitretinoin (1) · Fulvestrant (1) · Geritol (1) · Indomethacin (1) · Interleukin-2 (1) · Introns (1) · MLN8054 (1) · Omeprazole (1) · PAK inhibitor MRIA9 (1) · Paclitaxel (1) · Positron Emission Tomography Computed Tomography (1) · Proto-Oncogene Proteins c-raf (1) · Radiosurgery (1)
National Cancer Institute (NCI) (4) · University of Pennsylvania (3) · BriaCell Therapeutics Corporation (2) · G1 Therapeutics, Inc. (2) · AstraZeneca (1) · Carisma Therapeutics Inc (1) · Center Trials & Treatment (1) · Eisai Inc. (1) · Juravinski Cancer Center (1) · MBQ Pharma (1) · Millennium Pharmaceuticals, Inc. (1) · Providence Health & Services (1) · Takeda (1) · United BioPharma (1) · sigma-tau i.f.r. S.p.A. (1)
United States (16) · Bulgaria (2) · Georgia (2) · Moldova (2) · Taiwan (2) · Albania (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · South Korea (1) · Ukraine (1)
David Mankoff, MD, PhD (2) · George E Peoples, MD, FACS (2) · David Page, MD (1) · Do-Hoon Kim, BASc, MD, MSc, FRCPC (1) · Dr. Claudio Savulsky (1) · Elizabeth McDonald, MD, PhD (1) · Hsiang-Cheng Chen (1) · Jeanett Wetzel (1) · Julie Arsenault, MD, FRCPC (1) · Kevin Fox, MD (1) · Neil Sankar, MD (1) · Ronald E Gress, M.D. (1)
PMID 31836680, PMID 33413574, PMID 36441083, PMID 39726590, PMID 39920391
2014 (1), 2016 (1), 2017 (1)